Literature DB >> 31030279

Off-target genome editing: A new discipline of gene science and a new class of medicine.

Diane Catherine Wang1, Xiangdong Wang2.   

Abstract

With an increasing growth of genome editing, off-target effects such as non-specific genetic modifications resulting from the designed process of genome editing become a new discipline of gene science and new class medicine. The degree of short-term and long-term side effects and toxicity or dynamics of the primary and secondary off-target genome editing varies with the application of different methodologies of gene editing and measuring, readouts of genetic modifications, or comparison reference. Measurements of dynamic off-target effects caused directly or indirectly by genome editing are critical in clinical application of gene editing. The quality of genome editing methods is one of the decisive factors in the occurrence of off-target effects. Mechanisms by which off-target effects of genome editing occurs are more complex and comprehensive than we expected. The heterogeneity of off-target effects of gene-edited cells at single-cell levels should be defined during the development and formation of cell clusters. In addition to off-target effects on gene-edited cells per se, alterations of gene sequence, structure, dimension, and function of related regulators caused by off-target effects may also influence intercellular communications and interactions between gene-edited cells, between gene-edited cells and non-edited cells, or between non-edited cells. Thus, controlling, measuring, defining, categorizing, and predicting off-target genome editing need to be standardized and prioritized before clinical application of gene editing.

Entities:  

Keywords:  Gene editing; Off-target; Side effects; Therapy; Toxicity

Year:  2019        PMID: 31030279     DOI: 10.1007/s10565-019-09475-7

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  6 in total

1.  Minimizing off-target effects in CRISPR-Cas9 genome editing.

Authors:  Shi-Jie Chen
Journal:  Cell Biol Toxicol       Date:  2019-07-17       Impact factor: 6.691

Review 2.  Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications.

Authors:  Yue-Ying Huang; Xiao-Yu Zhang; Ping Zhu; Ling Ji
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 3.  Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems.

Authors:  Nannan Zheng; Liyang Li; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2020-01

4.  Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking.

Authors:  John J Kelly; Moe Saee-Marand; Nivin N Nyström; Melissa M Evans; Yuanxin Chen; Francisco M Martinez; Amanda M Hamilton; John A Ronald
Journal:  Sci Adv       Date:  2021-01-20       Impact factor: 14.136

Review 5.  An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology.

Authors:  Mina Roueinfar; Hayley N Templeton; Julietta A Sheng; Ka Lok Hong
Journal:  Molecules       Date:  2022-02-07       Impact factor: 4.411

6.  A refocus on the advances of single-cell biomedicine.

Authors:  William Wang; Xiangdong Wang
Journal:  Cell Biol Toxicol       Date:  2020-08-10       Impact factor: 6.691

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.